Fig. 5: Change in total bilirubin level (mg/dl) over time by UGT1A1 (rs4148325) genotype in A Sarilumab + DMARD-treated patients and B Placebo + DMARD-treated patients. | The Pharmacogenomics Journal

Fig. 5: Change in total bilirubin level (mg/dl) over time by UGT1A1 (rs4148325) genotype in A Sarilumab + DMARD-treated patients and B Placebo + DMARD-treated patients.

From: UGT1A1 genetic variants are associated with increases in bilirubin levels in rheumatoid arthritis patients treated with sarilumab

Fig. 5

Functional canonical correlation analysis (FCCA) was applied to test the association between the change in total bilirubin level over time and rs4148325 genotype (Interaction: rs4148325 genotype × treatment, p = 0.03).

Back to article page